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Abstract
Background: It is now well documented that critically ill patients are exposed to stressful conditions and
experience discomforts from multiple sources. Improved identification of the discomforts of patients in intensive
care units (ICUs) may have implications for managing their care, including consideration of ethical issues, and may
assist clinicians in choosing the most appropriate interventions. The primary objective of this study was to assess
the effectiveness of a multicomponent program of discomfort reduction in critically ill patients. The secondary
objectives were to assess the sustainability of the impact of the program and the potential seasonality effect.
Methods/design: We conducted a multicenter, cluster-randomized, controlled, single (patient)-blind study
involving 34 French adult ICUs. The experimental intervention was a 6-month period during which the
multicomponent program was implemented in the ICU and included the following steps: identification of
discomforts, immediate feedback to the healthcare team, and implementation of targeted interventions. The
control intervention was a 6-month period during which any program was implemented. The primary endpoint
was the monthly overall score of self-reported discomfort from the French questionnaire on discomforts in ICU
patients (IPREA). The secondary endpoints were the scores of the discomfort items of IPREA. The sample size was
660 individuals to obtain 80 % power to detect a 25 % difference in the overall discomfort score of IPREA between
the two groups (design effect: 2.9).
Discussion: The results of this cluster-randomized controlled study are expected to confirm that a multicomponent
program of discomfort reduction may be a new strategy in the management of care for critically ill patients.
Trial registration: ClinicalTrials.gov NCT02442934 , registered 11 May 2015.
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Background
It is now well documented that critically ill patients in
intensive care units (ICUs) are exposed to stressful
conditions and experience discomforts from multiple
sources [1–7]. These forms of discomforts, also called
stressors, may be differentiated into the following three
categories: environmental discomforts (noise, excessive
light); discomforts related to the specific organization of
ICU care (frequent monitoring, short timeslots for visi-
tors, unavoidable isolation); and discomforts related to
the health state of the patient and the care provided
(pain, mechanical ventilation or noninvasive ventilation,
gastric tube, intravenous access, urinary probe, pleural
drain). Some authors have distinguished the discomforts
into two other categories: physical (pain, sleep deprivation,
thirst, hunger, feeling of cold, feeling of heat) and psycho-
logical (communication restriction, lack of autonomy,
isolation, anxiety, no respect for intimacy) [3]. These may
have significant short-term and long-term consequences
for the patients, such as agitation and/or confusion during
the ICU stay, which is also called ICU delirium [8–11], or
various degrees of anxiety and/or depression [12] or post-
traumatic stress disorder after the ICU stay [13–15] that
may affect their quality of life [16]. Indirect consequences
could also be related to the general representation of the
ICU as interpreted by the patients themselves or by
their relatives, and patients may develop a fear of the ICU
[17, 18]. This could lead to late admissions to the ICU and
worsened organ functions, which may impact patient
outcomes.
Quantification of discomforts is commonly performed
using standardized methods as well as objective or sub-
jective measures. Quantification of noise [19] or lighting
[20] and quantification of physiologic parameters [21]
were used as stressor indicators, but they did not en-
tirely explore patient discomfort, especially the self-
perceived discomfort. Patient-reported outcomes are
now considered a better picture of patient feelings and
perceptions compared to objective indicators [2, 4, 6, 7]
that have led to the development of several ICU-related
perceived discomfort tools [3, 4]. Recently, a well-
validated questionnaire of self-perceived patient discom-
forts related to an ICU stay, the IPREA, has been
proposed. The IPREA is differentiated from other tools
by a validation process based on international guidelines
and is performed using a large sample (n = 868) of unse-
lected critically ill patients hospitalized in different types
of ICUs (medical, surgical, and mixed medical–surgical)
in different institutions (university and non-university
hospitals) and a large range (n = 16) of discomforts.
Moreover, the IPREA allows the possibility of obtaining
a synthetic overall discomfort score [22].
Different actions have previously demonstrated effect-
iveness in correcting and reducing specific discomforts.
The optimization of alarm management and monitoring,
the control of the sound level during verbal transmis-
sions between the teams, and the implementation of
music sessions, cycling light, and unrestrictive visiting
policies have been shown to be efficacious in experimen-
tal and/or controlled studies [23–27]. These actions gen-
erally focus on one single discomfort, but they have not
addressed a more global approach.
An alternative intervention can be proposed. The
"assessment-feedback" approach, which combines sys-
tematic assessment with feedback to the healthcare
teams, previously demonstrated its effectiveness by sen-
sitizing the healthcare team. For example, patient satis-
faction assessment combined with feedback has emerged
as an important source of information for screening spe-
cific problems and developing effective plans of action
for quality improvement in healthcare organizations
[28]. Also, assessment of patients’ quality of life with sys-
tematic feedback to clinicians has been shown to im-
prove patient–physician communication and patient
satisfaction in oncology and psychiatry [29–32]. In the
specific context of the ICU, we can hypothesize that sys-
tematic assessment/feedback of discomforts may also
highlight specific discomforts, may have implications for
managing care, including considerations of ethical issues,
and may assist the healthcare teams in choosing the
most appropriate interventions. The identification of
specific discomforts may allow for implementing min-
imal interventions expediently or developing more com-
plex actions. To date, no randomized controlled study
has assessed the impact of an "assessment" of discom-
forts and "feedback" to ICU healthcare teams.
These observations prompted us to establish a multicen-
ter, cluster-randomized, controlled study with the object-
ive of assessing the effectiveness of a multicomponent
program of discomfort reduction in critically ill adult pa-
tients. This program combines three main components:
assessment and identification of discomforts; feedback to
the healthcare workers; and implementation of corrective
actions. We hypothesized that this program may have a
positive effect on the discomfort level self-reported by crit-
ically ill patients.
Objectives
The primary objective was to assess the effectiveness of
the multicomponent program of discomfort reduction in
the ICU. The secondary objectives were to assess sustain-
ability and a potential seasonality effect of this program.
Methods/design
Design
The study design was built to achieve both the primary
and the secondary objectives. To achieve the primary
objective, a multicenter, cluster-randomized, controlled,
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single (patient)-blind, two-parallel group study was de-
signed using the recommendations of the Consolidated
Standards of Reporting Trials (CONSORT extension for
Cluster Trials) statement [33]. The cluster level com-
prises the ICUs, which are the units of randomization.
Patients hospitalized in the ICUs comprise the individual
level. All ICUs start with a 1-month period with no
intervention, and then they are randomized to one of
two groups: a 6-month period during which the multi-
component program (experimental group) is imple-
mented or a 6-month period during which any program
(control group) is implemented.
To assess the sustainability of the impact of the pro-
gram, the study was completed with a second 6-month
period during which the program was no longer applied
in the ICUs randomized to the experimental group. Dur-
ing this second 6-month period, the program was applied
in the ICUs randomized to the control group. We hypoth-
esized that the multicomponent program of discomfort
reduction is considered attractive for caregivers in the par-
ticipating ICUs, leading to an initial preference for the in-
vestigators to be randomized to the experimental group.
The inferred risk is better adherence to the study in the
ICUs randomized to the experimental group in compari-
son with the other ICUs randomized to the control group
and, therefore, an imbalance in the number of included
patients in the two groups. That is the reason why the
study was designed to offer the opportunity to all the
ICUs to implement the program, no matter when the
cluster randomization may occur (whether during the first
6-month period or during the second 6-month period).
Moreover, the prolongation of the study for a 6-month
period (leading the ICUs that were initially randomized
to the control group to test the program) allows assess-
ment of the potential seasonality effect of the program
(because the program will be applied during another
part of the year) and the ability to obtain eventual con-
firmation of the impact of the program in other ICUs.
Thus, five periods are differentiated and illustrated in
Fig. 1. Period 1 lasts 1 month, during which none of the
34 ICUs apply the multicomponent program. All the eli-
gible patients can be included and can be assessed using
the self-perceived discomfort questionnaire, but no feed-
back of scores will be given to the healthcare teams.
Thus, baseline discomfort levels will be available. Period
2 lasts 5 months, during which the 17 ICUs randomized
to the experimental group will implement the multicom-
ponent program as detailed below, whereas the 17 ICUs
randomized to the control group will not implement it.
Period 3 lasts 1 month, during which all the eligible pa-
tients of the 34 ICUs can be included and can be
assessed using the self-perceived discomfort question-
naire. The 17 ICUs randomized to the experimental
group will continue to apply the program with feedback
information (last month of the 6-month period for im-
plementation of the program), whereas the 17 ICUs ran-
domized to the control group will receive no feedback.
Period 4 lasts 5 months, during which the 17 ICUs ini-
tially randomized to the control group will implement
the multicomponent program as detailed below, whereas
the 17 ICUs initially randomized to the experimental
group will no longer implement it. Period 5 lasts
1 month, during which all the eligible patients of the 34
ICUs can be included and can be assessed using the self-
perceived discomfort questionnaire. The 17 ICUs ran-
domized to the control group will continue to apply the
Month M1 M2 M3 M4 M5 M6 M7 M8 M9 M10 M11 M12 M13
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The MCP is not yet implemented in the control group
Fig. 1 MCP: Multicomponent program
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program with feedback information (last month of the
6-month period for implementation of the program),
whereas the 17 ICUs randomized to the experimental
group will receive no feedback.
Partners
Dr. Pierre Kalfon, coordinating investigator, Les Hôpitaux
de Chartres (France), is responsible for the study. The
methodological support will be provided by the Clinical
Research Unit (Unité Aide Méthodologique à la Recherche
Clinique, AP-HM, France) and the Self-Perceived Health
Assessment Research Unit (Aix-Marseille University,
Marseille, France). A steering committee includes the co-
ordinating investigator, six French ICU experts, and three
nursing managers, each of them working in one partici-
pating ICU center, and the head of the Clinical Research
Unit (see Table 1 for composition and affiliations of the
members of the steering committee). This committee will
have the role of elaborating a set of recommendations to
prevent each discomfort explored by the 16-item ques-
tionnaire. This set of recommendations consists of short
sentences that may be considered a minimal charter for
reducing the main discomforts perceived by the patients
hospitalized in the ICU. This committee can also control
the proper conduct of the trial in terms of methodological,
ethical, and logistical aspects.
The study will be performed in 34 French adult ICUs
under the supervision of 29 co-investigators (Table 1).
This work is supported by institutional grants from the
French 2012 Programme Hospitalier de Recherche
Clinique National.
Participants
The participating ICUs will comprise the cluster level
and the patients managed in the participating ICUs will
comprise the individual level. Inclusion and exclusion
criteria are provided for each level unit. The details of
the inclusion and exclusion criteria of clusters and indi-
viduals are provided in Table 2 and Table 3, respectively.
Eligibility criteria for ICUs
Eligible ICUs may have the following main criteria: adult
ICU; presence of a voluntary physician–nurse pair who
accept the role of local champions to reduce patient dis-
comforts and coordinate the whole program based on
targeted interventions; and no planned implementation
of other interventions that may affect discomfort during
the study period.
Eligibility criteria for patients
The main inclusion criteria are the following: age
18 years or older; admitted to one of the included ICUs
during the predetermined study period with ICU stay of
3 calendar days or more; and alive on the day of ICU
discharge. The main exclusion criteria are the following:
deceased patient during the ICU stay; ICU stay of 2 calen-
dar days or less; patient younger than age 18 years; patient
under trusteeship; patient refusing to participate in the
study; patient with diminished mental capacity; patient
not understanding French sufficiently to be questioned;
patient transferred to another ICU while mechanically
ventilated; and emergency discharge. In accordance with
French law, oral consent will be obtained from each
participant after delivery of the study objectives and impli-
cations of the potential participation.
Experimental and control interventions
Experimental intervention: the multicomponent program
During a 6-month period, the ICUs randomized to this
group will apply the multicomponent program. Before
the beginning of the program, the following proceedings
will be achieved. Guidelines will be elaborated by the
steering committee containing concise recommenda-
tions to prevent each discomfort item that should be
used as reminder messages to healthcare teams. In each
ICU, two local champions, an ICU physician involved in
the continuity of care and the ICU managing nurse or
another experimented nurse to substitute the ICU man-
aging nurse in case of absence, are identified before the
beginning of the program. These two people will be in
charge of the local coordination of the program. Each
participating ICU will be supplied with tablets with
Internet connection unless each room in the ICU is
equipped with a computer and Internet access. To
optimize the inclusion of potentially eligible patients, the
bedside nurse will have to enter patient demographic
data in an anonymized form starting from the day of
ICU admission (prescreening process). On the day of
ICU discharge, the bedside nurse will find the patient,
whose information has already been entered; the nurse
will connect to the electronic-specific database and will
test eligibility and exclusion criteria by following a step-
by-step approach (screening process). If the patient pre-
sents eligibility criteria and has no exclusion criteria,
then the bedside nurse will have to assess the discom-
forts perceived by the patient. To ensure adequate train-
ing of the nursing staff, the application (access to the
specific website and use of a preproduction database)
will be used in each ICU for a training period of several
weeks with technical and educational support provided
by the coordinating investigator and the coordination
team before the first patient is included.
The program comprises the following three stages:
1. Discomforts assessment: a web-based systematic
measurement of the patient discomforts will be
performed using IPREA by the bedside/institutional
caregiver (including nurses and assistant nurses) in
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charge of the patient (presented in Table 4). On the
day of ICU discharge, the nurse (or the assistant
nurse) will ask patients to rate the severity of each
discomfort experienced during the entire stay in the
ICU (not just during the last day in the ICU) using a
10-point numerical rating scale. Each discomfort is
scored on a scale from 0 to 10 (example: 0 = no pain
and 10 = worst pain possible). A random process will
allow the nurse to ask the patient in a random order
to reduce contamination between items.
2. Feedback of discomfort scores: two kinds of
feedback will be organized. First, immediate
feedback corresponding to the three discomforts
reported with the highest scores by the patient will
be forwarded to the bedside/institutional caregiver.
Concise messages used as reminders (from the set of
recommendations previously elaborated by the
steering committee) will be displayed on the screen
before the application is closed by the nurse or the
assistant nurse. Moreover, the overall discomfort
score will be automatically calculated and presented
on the screen to the nurse at the end of the
administration of IPREA. Second, monthly and
cumulative discomfort scores and their relative
Table 1 Coordinating investigators, co-investigators, healthcare
workers, methodology and biostatistics team, and steering
committee
Hospitals (all in France)
Coordinating investigator
Dr. Pierre Kalfon Hôpital Louis Pasteur, CH de Chartres, Chartres
Co-investigators
(alphabetical order)
Pr. Julien Amour CHU Pitié-Salpêtrière, AP-HP, Paris
Pr. Elie Azoulay CHU Saint-Louis, AP-HP, Paris
Dr. Audrey Berric Hôpital Sainte-Musse, CH intercommunal de
Toulon – La Seyne-sur-mer, Toulon
Dr. Claire Boulle-
Geronimi
CH de Douai, Douai
Dr. Olivier Collange CHU Hôpital Civil, Strasbourg
Dr. Philippe Estagnasie Clinique Ambroise Paré, Neuilly-sur-Seine
Dr. Bernard Floccard CHU Edouard Herriot, Lyon




Groupe Hospitalier Paris Saint-Joseph, Paris
Pr. Carole Ichai CHU Saint-Roch, Nice
Dr. Quentin Levrat Groupe Hospitalier de La Rochelle - Ré –
Aunis, La Rochelle
Pr. Claude Martin CHU Hôpital Nord, AP-HM, Marseille
Pr. Olivier Mimoz CHU La Milétrie, Poitiers
Dr. Martine Nyunga Hôpital Victor Provo, CH de Roubaix, Roubaix,




Pr. Catherine Paugam CHU Beaujon, AP-HP, Clichy
Pr. Julien Pottecher CHU Hautepierre, Strasbourg
Pr. Jean-Pierre Quenot CHU Dijon Bourgogne, Dijon
Dr. Anne Renaud CHU Hôpital de la Cavale Blanche, Brest
Pr. René Robert CHU La Milétrie, Poitiers
Dr. Thomas Signouret Hôpital Européen de Marseille (HEM), Marseille
Dr. Georges Simon CH de Troyes, Troyes
Dr. Achille Sossou CH Emile Roux, Le Puy en Velay
Pr. Tarek Sharshar CHU Raymond Poincaré, AP-HP, Garches
Dr. Antoine Tesniere CHU Cochin, AP-HP, Paris
Dr. Didier Thévenin CH de Lens, Lens
Dr. Marion Venot
Dr. Coralie Vigne





Chief nurse, CHU Dijon Bourgogne, Dijon
Mrs. Nathalie Revel Chief nurse, CHU Saint-Roch, Nice
Mrs. Isabelle Villard Chief nurse, CHU Beaujon, AP-HP, Clichy
Table 1 Coordinating investigators, co-investigators, healthcare




Pr. Pascal Auquier EA3279 Self-perceived Health Assessment
Research Unit Aix-Marseille University, Marseille,
France and Department of Epidemiology and




Dr. Pierre Kalfon (chair) Hôpital Louis Pasteur, CH de Chartres, Chartres
Pr. Pascal Auquier EA3279 Self-perceived Health Assessment
Research Unit Aix-Marseille University, Marseille,
France and Department of Epidemiology and
Health Economy, AP-HM, Marseille
Pr. Olivier Mimoz CHU La Milétrie, Poitiers
Mrs. Marie-Agnès
Geantot
Chief nurse, CHU Dijon Bourgogne, Dijon
Mrs. Nathalie Revel Chief nurse, CHU Saint-Roch, Nice
Mrs. Isabelle Villard Chief nurse, CHU Beaujon, AP-HP, Clichy
Pr. Julien Amour CHU Pitié-Salpêtrière, AP-HP, Paris
Pr. Elie Azoulay CHU Saint-Louis, AP-HP, Paris
Dr. Maité Garrouste-
Orgeas
Groupe Hospitalier Paris Saint-Joseph, Paris
Pr. Claude Martin CHU Hôpital Nord, AP-HM, Marseille
Pr. Tarek Sharshar CHU Raymond Poincaré, AP-HP, Garches
Note: CH = Centre Hospitalier (community hospital); CHU = Centre Hospitalier
Universitaire (academic tertiary care hospital); AP-HP = Assistance Publique -
Hôpitaux de Paris; AP-HM = Assistance Publique - Hôpitaux de Marseille
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ranking compared to other ICUs assigned to the
experimental group will be forwarded each month to
the local champions by the coordination team.
3. Targeted interventions: an implementation of
targeted interventions based on the monthly
feedback will be planned in each ICU to reduce
discomforts. Once the local champions have
received the results of their ICUs, they will organize
a meeting with their ICU team to present and
comment on their results. At the end of these
monthly meetings, the local champions will consult
with the staff (physicians, nurses and assistant
nurses, psychologists if regularly present in the ICU)
and select appropriate actions. These actions may
correspond to the most important perceived
discomforts in the ICU, those perceived at a higher
level in comparison with the other ICUs randomized
in the experimental group, or those that appear
most easily preventable. During these meetings, local
champions will also assess the effectiveness of
previously decided measures, identify any barriers to
implementation, and suggest solutions to resolve
these barriers. It is important to note that the
measures implemented in the ICU are not decided by
the steering committee or by the coordination team.
The local champions consult with their staff to define
the best targeted measures for their ICUs. Therefore,
these measures will be different from one ICU to
another. After each monthly meeting, local
champions will send the meeting report with the list
of participants to the coordination team. Beyond this
role of meeting moderators, the local champions will
raise the awareness of the staff about discomfort
prevention and disseminate and facilitate the ongoing
measures for discomfort prevention on a daily basis.
Control intervention: usual care management
During a 6-month period, the ICUs will apply any spe-
cific program. The control period will be based on usual
care management. However, during the last month of
this 6-month period, the caregivers will have to assess
discomfort among the eligible patients without receiving
any type of feedback.
Randomization of clusters
Active consultation is conducted by the coordinating in-
vestigator among ICU heads in each potential participat-
ing ICU to ensure agreement regarding implementation
of the program on the ICU level. Computer-generated
randomized lists will be drawn up before the beginning
of the study using a permuted block design, for which
the clinical research unit (AP-HM) will be responsible.
The randomization will be stratified by the average
monthly number of patients not deceased during ICU
discharge during the year preceding the start of the
study (three levels were considered: ≤35, 36–59, and
≥60). The randomization will assign each ICU (1:1 allo-
cation ratio) to either control or experiment. The inves-
tigators and caregivers will not be blinded, but all
participants will be unaware of the ICU allocation.
Data collection
The following ICU-specific parameters will be recorded:
type of ICU (medical, surgical, or mixed medical–surgi-
cal); number of beds; mean of stay duration; annual
mortality rate.
Data related to the patient will be recorded from an
electronic case report form (eCRF) specifically elabo-
rated for the study. The following data will be collected:
demographics (sex, age); health status before the ICU
stay using the Knaus score [34] and the McCabe index
[35]; health status at ICU admission using the Simplified
Acute Physiology Score (SAPS II) [36]; type of admission
(medical, scheduled surgical, or emergency surgical);
health status from the ICU admission to ICU discharge
(use and duration in days of mechanical ventilation,
noninvasive ventilation, administration of vasopressors,
renal replacement therapy, type and number of invasive
procedures, sedation duration, delay between interrup-
tion of the sedation and discharge from the ICU); and
Table 2 Selection criteria of ICUs
Inclusion criteria - Adult ICU
- Medical, surgical, or medical–surgical ICU
- Agreement of the chief responsible
- Willingness to be randomly allocated to one of the
two groups
- Presence of a voluntary physician –nurse pair
- No planned interventions that may affect
discomfort during the study period
Exclusion criteria - ICU with an expected recruitment ratio (number
of collected questionnaires/number of eligible
patients) <0.6
Table 3 Selection criteria of patients
Inclusion criteria - Adult patients (≥18 years of age) of either sex
- Subject discharged from one of the included ICUs
during one of the 1-month periods P1, P3, or P5) (Fig. 1)
- Subject with ICU stay of 3 calendar days or more
- Subject alive on ICU discharge day
- Subject consenting to participate in the study
Exclusion criteria - Minors
- Subject under trusteeship
- Subject deceased during the ICU stay
- Subject with ICU stay of 2 calendar days or less
- Subject transferred to another ICU while mechanically
ventilated
- Subject with emergency discharge
- Subject with diminished cognitive capacity based on
the investigator’s opinion
- Subject not consenting to participate in the study
- Subject misunderstanding the written and spoken
French language
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self-perceived discomforts (IPREA, see the Endpoints
section) assessed on the day of ICU discharge during the
specific periods of assessment.
Endpoints
The endpoints pertain to the individual level. Patient
discomfort will be assessed using the French self-
reported discomfort IPREA questionnaire ("Inconforts
des Patients de REAnimation": Discomforts perceived by
ICU patients) [22]. IPREA is a well-validated specific
questionnaire that is elaborated using standard proce-
dures. This self-reported questionnaire includes 16 dis-
comfort items: noise; excess of light; discomfort related
to sleeping in a bed different from the one the patient
has at home; sleep deprivation; thirst; hunger; feeling of
cold; feeling of heat; pain; being tied down by perfusion
lines, tubes, or as a result of connections due to moni-
toring devices; no respect for intimacy; anxiety; isolation;
limited visiting hours; absence of phone; and lack of in-
formation. Each item is scored from 0 (minimal discom-
fort) to 10 (maximal discomfort). The overall discomfort
score is calculated as the mean of all the scores reported
for each discomfort item multiplied by 10, yielding an
overall discomfort score between 0 (minimal overall dis-
comfort) and 100 (maximal overall discomfort). The
questionnaire is administered on the day of ICU dis-
charge. The time frame considers the period from the
date of admission to the ICU until the day of discharge
from the ICU.
Primary endpoint
The primary endpoint is the monthly overall discomfort
score of the 16-item IPREA (mean of all the overall dis-
comfort scores available during the month).
Secondary endpoints
The secondary endpoints are the monthly discomfort
scores of the 16 items included in IPREA.
Statistical considerations
Sample size, power, and statistical methods
The sample size was determined to detect a 25 % differ-
ence in the overall score of IPREA between the two
groups. This 25 % difference, considered to be clinically
significant, was based on a previous report indicating a
mean overall discomfort IPREA score of 22 (standard de-
viation of 14). The intracluster correlation coefficient
(ICC) was estimated from the database of the IPREA
questionnaire validation study. With a design effect calcu-
lated to be 2.9 (ICC = 0.1; expected equal cluster sizes =
Table 4 The French IPREA questionnaire for assessing self-reported discomforts perceived by the critically ill patients, original
version
1 Avez-vous souffert du bruit (alarmes, radios, sonneries de téléphone, conversations) de jour comme de nuit?
2 Avez-vous souffert de la lumière (éclairage trop important dans la chambre ou dans le couloir surtout la nuit?
3 Avez-vous souffert du lit (matelas trop dur ou trop mou, matelas à eau, tête de lit trop ou pas assez relevée, lit trop bas ou trop haut, barrières,
mauvais oreillers, etc.)?
4 Avez-vous souffert du manque de sommeil par rapport à d'habitude?
5 Avez-vous souffert de la soif?
6 Avez-vous souffert de la faim?
7 Avez-vous souffert du froid?
8 Avez-vous souffert de la chaleur?
9 Avez-vous eu des douleurs, même si elles étaient présentes avant l'hospitalisation, y compris les douleurs liées aux piqûres ou lors des changes
ou de la toilette matinale?
10 Avez-vous souffert d'être entouré de tuyaux (pour les perfusions, les connections des électrodes fixées sur le thorax, l'oxygène dans le nez ou sur
le masque, la pince pour surveiller l'oxygénation, etc.)?
11 Avez-vous été gêné par le fait que votre intimité ne soit pas suffisamment respectée (par ex. pendant la toilette matinale, les changes, l'examen
par les médecins, ou les visites médicales)?
12 Avez-vous souffert d'angoisse (peur parfois panique par exemple qu'un appareil important fonctionne mal, provoquée parfois par le
déclenchement d’alarmes sonores) ou vous êtes vous senti très anxieux durant votre hospitalisation?
13 Avez-vous souffert d’isolement (être seul dans votre chambre, parfois sans voir d'infirmiers ou de médecins à proximité) et sans entendre de
bruit?
14 Avez-vous été gêné par la limitation des visites des membres de votre famille ou de vos amis selon les horaires de visite en vigueur dans le
service?
15 Avez-vous été gêné de ne pas avoir de téléphone dans la chambre?
16 Avez-vous été gêné de n'être pas assez informé de votre état ou de ce qu'on allait vous faire, de l'évolution de votre maladie, de votre date de
sortie de réanimation, des suites, que ce soit par les infirmières ou les médecins?Note: each discomfort item is in bold
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20), a two-sided significance level of 5 %, and 80 % power,
630 IPREA scores are needed (315 in each group) to de-
tect this difference. To prevent 10 % of the questionnaires
being unusable or invalid, a total of 700 individuals should
be included.
Data analysis
The data will be analyzed using SPSS version 17.0 soft-
ware and SAS/STAT® version 9.2.
The primary (overall score of IPREA) and secondary
(16-item scores of IPREA) endpoints will be analyzed on
the individual patient level using cluster level summar-
ies, which will account for the correlation between pa-
tients in the same center. Analysis methods based on
individual patient-level data perform well when the
number of clusters is high [37]. The overall score of dis-
comfort and the scores for each item will be compared
between control and experimental groups. No interim
analysis is planned.
The primary analysis will be performed on the
intention-to-treat population corresponding to all in-
cluded individuals in each participating ICU. A second-
ary analysis will be performed on the per-protocol
population corresponding to all included individuals
who complete the IPREA questionnaire. Supplementary
sensitivity analyses will be performed on a subgroup of
ICUs corresponding to ICUs with a recruitment ratio
(ratio of number of collected questionnaires to eligible
patients) higher than 0.7, 0.8, and 0.9.
Descriptive analyses will provide ICU and patient char-
acteristics for each group (control and experimental
groups). The normality of the parameters will be esti-
mated using frequency histograms and the Shapiro test.
Comparisons between the two groups will be performed
using the main individual characteristics using chi-
squared tests or Fisher exact tests for qualitative vari-
ables and Student t-tests or Mann–Whitney tests for
continuous variables.
All analyses will account for clustering to ensure cor-
rect type I error rates and confidence intervals [38]. Ap-
propriate statistical methods to account for clustering
between patients in the same cluster will be performed
using linear mixed-effects models or generalized estimat-
ing equations with inclusion of random effects for indi-
vidual ICUs and assessment of possible confounding.
The primary endpoint (mean of the overall discomfort
scores collected during the 1-month period, B versus E
in Fig. 1) will be analyzed without adjustment by com-
parison of IPREA scores between the two groups using
Student t-tests or Mann–Whitney tests according to the
variable distribution. A set of secondary analyses will be
adjusted for covariates of clinical interest using general-
ized linear mixed regression models including the group
(interventional/control), ICUs and individuals (as
random variables), a priori covariates (patient age, gen-
der, ICU stay duration, mechanical ventilation duration,
and type of admission), and other co-variables selected
with a threshold p-value <0.05 during univariate analysis.
These models will be performed using the MIXED SAS
procedure (version 9.2). The same procedure will be per-
formed on the 16 IPREA scores for each discomfort item
(B versus E in Fig. 1).
Generalized linear mixed regression models will be
performed to assess the sustainability of the effect by
comparison of monthly means of overall discomfort
scores collected during periods P3 and P5, respectively,
reported by patients included in the experimental group
at 6-month intervals (B versus C in Fig. 1) and the sea-
sonality effect by comparison of monthly means of over-
all discomfort scores collected during periods P1 and P3,
respectively, reported by patients included in the control
group at 6-month intervals (D versus E in Fig. 1).
Ethical aspects, laws, and regulations
The study will be conducted in accordance with the
Helsinki Declaration, French laws and regulations (Code de
la Santé Publique, article L.1121-1/Loi de Santé Publique
no. 2004–806 du 9 août 2004 relative à la politique de
santé publique et ses décrets d’application du 27 août 2006),
and the International Conference on Harmonization (ICH)
E6 Guideline for Good Clinical Practice. Regulatory moni-
toring will be performed in accordance with the French law
requiring the approval of the French ethics committee
(Comité de Protection des Personnes Tours Région Centre-
Ouest 1, 28 August 2013, reference number 2013-S10). All
records and subjects’ identities will remain confidential in
accordance with the following French regulations: the
French National Committee of Informatics and Liberties
(Commission nationale de l’informatique et des libertés, 20
March 2014, reference number DR-2014-097) and the
French Consultative Committee for Data Processing in
Health Research (Comité consultatif sur le traitement de
l’information en matière de recherche dans le domaine de
la santé, 12 December 2013, reference number 13.642bis).
Oral consent will be collected for each participant.
Discussion
To our knowledge, this is the first study assessing the ef-
fectiveness of a program of discomfort reduction for
ICU patients using a randomized controlled design,
which is the most appropriate design to demonstrate the
efficacy of a new experimental intervention in accord-
ance with the levels of evidence classification of the
Evidence-Based Medicine Working Group (Evidence-
Based Medicine Working Group 1992; produced by Bob
Phillips, Chris Ball, Dave Sackett, Doug Badenoch,
Sharon Straus, Brian Haynes, and Martin Dawes since
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November 1998; updated by Jeremy Howick in March
2009).
We hypothesize that routine assessment of patient dis-
comforts will be useful for further investigation and im-
plementation of targeted preventive/curative actions. A
previous study using the IPREA questionnaire for pa-
tient discomforts assessment has shown that most of the
identified discomforts may be relatively easily relieved by
interventions conducted by the ICU team. This program
is in accord with the message of the 2009 French con-
sensus conference centered on “a better life in ICU,”
which lists recommendations to reduce stressors and
discomforts. This program is based on the "plan-do-
check-act" (PDCA), which is a management method for
the control and continuous improvement of widespread
processes and products in business and contributes to
quality management and continuous quality improve-
ment in healthcare [39]. The PDCA involves the planning
and selection of interventions intended to improve the se-
lected process, implementation of the selected interven-
tion, assessment of its effectiveness, and embedding of
changes into the existing quality improvement structure.
If this program is effective, then it may provide a signifi-
cant improvement in the negative experiences reported by
ICU patients, such as stressors and discomforts.
However, some issues related to this specific protocol
study should be developed. First, the choice of a cluster
design should be discussed. Because the experimental
program is applied to the whole ICU and affects all the
individuals within the ICU, the individual randomization
will not be appropriate [40]. To fit the intervention ap-
plication and to avoid contamination within the unit,
cluster randomization is advocated [41, 42]. However,
one bias should also be taken into account: because of
the consecutive inclusion of patients, there is a greater
chance of fluctuations, potentially causing selection bias,
which needs to be assessed and adjusted for if present.
The cluster approach has previously addressed pertinent
issues of ethics. The decision regarding whether a par-
ticular cluster will participate in the trial is made by one
single person (also called a guardian in a previous debate
article) who decides to participate on the behalf of the
cluster [41]. In this work, the authors noted that guard-
ians, like physicians in conventional trials, might have
potential conflicts of interest and/or scientific interests
in the results. In our specific case, the guardian is gener-
ally the head of the ICU and is in a position to volun-
teer. The coordinating investigator contacted each of
them, and we can assume that any policy-maker or chief
executive of the hospital participated in making the deci-
sion. In the same way, the consent of the patient to par-
ticipate or not is not really applicable. If a patient
declines participation, then we can only ensure that the
discomforts assessment will not be performed. However,
the multicomponent program will be implemented
throughout the whole ICU.
Second, the option of parallel design may be discussed.
Although the large differences in patient populations be-
tween ICUs should lead us to prefer a crossover design
(between-group and within-group comparisons will also
be permitted [43]) over a parallel design, crossover trials
imply having no carryover effect. The carryover effect
corresponds to an effect that "carries over" from one ex-
perimental condition to another [44] that could poten-
tially distort the results obtained during the second
period (the experimental condition from the first time
period may impact the effectiveness of the experimental
condition during the second time period). In our specific
case, it was not possible to hypothesize that the imple-
mentation of the multicomponent program during the
first time period (6 months) would not have an effect on
the second time period. The implementation of targeted
interventions in the ICU will probably lead to changes in
the behavior of healthcare professionals. Therefore, the
observed effects will depend on the order in which the
interventions will be applied [45]. We have decided that
any washout period will be sufficient to prevent this car-
ryover effect [46, 47]. Moreover, this design allows us to
assess the potential sustainability of the effect of pro-
gram implementation. Assessment of sustainability is an
important goal of evidence-based medicine and evidence-
based practice to ensure that research findings are
translated into clinical practice [48]. Effectiveness (and im-
plementation) studies must particularly examine the local
circumstances in which the programs would be applied
and necessarily adapted. There are no data regarding sea-
sonality, but the case mix of diseases may be different
from a period of one year to another. Therefore, it could
be hypothesized that perceived discomforts might vary
according to the main diagnosis leading to admission to
the ICU.
Third, the fact that the healthcare team will not be
blinded should be considered in the interpretation of the
final results. The implementation of a program of dis-
comfort reduction associated with systematic assessment
of patient discomforts may have a direct influence on
healthcare behaviors. The caregivers could make more
of an effort than usual, leading to better attention to the
patient’s discomfort and the potential sources of discom-
fort. This phenomenon is well described and is known
as the Hawthorne effect, and it may involve underesti-
mation of the intervention effect [49, 50]. This potential
Hawthorne effect was actually desired during the imple-
mentation of the program and must be considered as
the first stage of the multicomponent program, but this
effect also applies during the baseline assessment period.
Therefore, the Hawthorne effect, if present, could induce
an artificial reduction in the overall discomfort score
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due to the implementation of the program. Suppressing
this potential bias would have required administration of
IPREA by actors not in the ICU and without knowledge
by the ICU team, which is impracticable.
Despite the acknowledged need to consider discomfort
issues, self-reported assessment remains underutilized in
clinical practice. Environmental barriers have been de-
scribed to explain why self-reported measures have not
been routinely implemented in clinical practice [51, 52].
Time and resources are both constraints on clinicians,
whose main role is to provide patient care. The ergo-
nomics of the questionnaire, such as shorter length, an
electronic format, or computer-adaptive testing, may im-
prove the acceptability [53, 54]. Although the psycho-
metric properties and acceptability of the IPREA
questionnaire are satisfactory, the development and val-
idation of shorter or web versions should be considered
to improve its implementation and use in routine clin-
ical practice.
In conclusion, the results of this cluster-randomized
controlled study are expected to confirm that a multi-
component program of discomfort reduction may be a
new strategy for the care of critically ill patients.
Trial status
At the time of first manuscript submission, the trial was
currently recruiting participants. The study completion
date was October 2015.
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